The Kiniksa Conundrum: A Cautionary Tale for Long Term Investors Kiniksa Pharmaceuticals' recent quarterly sales report has sparked investor interest, but beneath its impressive revenue growth lies a more nuanced story.
This tale highlights the dangers of getting caught up in short term gains and investing in biotech stocks without considering the broader implications.
The company's flagship drug, Arcalyst, has shown promising results in treating recurrent pericarditis.